If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Lyumjev Summary of Product Characteristics (SmPC)
Lyumjev® ▼ (insulin lispro): Treprostinil and Platelet Inhibition
In the absence of systemic exposure of treprostinil, no inhibitor effect on platelet function is expected after injection of Lyumjev.
Treprostinil
- Platelet Inhibition
In
the absence of systemic exposure, no inhibitor effect on platelet
function is expected.1
The
dose of 10 ng of treprostinil does not show detectable circulating
levels, and no systemic effects are shown.1
In
the formulation of Lyumjev, microdoses of treprostinil are used
as an excipient to increase blood flow at the site of injection
through localized vasodilation.2-4
The
commercial formulation of Lyumjev contains 10 ng of treprostinil per
unit of insulin lispro in a 100 unit/mL formulation.1
References
1.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2.
Leohr J, Pratt E, Heilmann C, et al. Treprostinil causes local
vasodilation is well tolerated, and results in faster absorption of
insulin lispro [abstract]. Diabetologia. 2017;60(suppl
1):S313. http://dx.doi.org/10.1007/s00125-017-4350-z
3.
Leohr J, Pratt EJ, Heilmann C, et al. A novel insulin lispro
formulation containing citrate and treprostinil demonstrates faster
absorption and onset of insulin action in healthy subjects
[abstract]. Diabetes. 2017;66(suppl 1):A253.
http://dx.doi.org/10.2337/db17-890-1488
4.
Pratt E, Leohr J, Heilmann C, et al. Treprostinil causes local
vasodilation, is well tolerated, and results in faster absorption of
insulin lispro [abstract]. Diabetes. 2017;66(suppl 1):A253.
http://dx.doi.org/10.2337/db17-890-1488
▼ This
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:July 19, 2019
Was this answer helpful to you?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com